By Doug Macron

With its ability to down-regulate almost any gene of interest, RNAi has been touted as a technology with almost limitless therapeutic potential, capable of hitting targets that have eluded traditional modalities such as small molecules.

Despite this promise, companies working in the space have taken a decidedly measured approach in building their internal pipelines, focusing on a relatively small number of drug-development programs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Patients who've learned their genetic risk of disease worry about healthcare law changes in the US, Kaiser Health News reports.

Hopkins' Geoffrey Ling discusses the promise of genomic vaccines at Scientific American.

In Nature this week: mitochondrial genome of extinct South American ungulate, and more.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.